ID
23025
Beschrijving
NCT00340080 / VIIV-CNA106030 https://clinicaltrials.gov/ct2/show/NCT00340080 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Week 1 Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV
Link
https://clinicaltrials.gov/ct2/show/NCT00340080
Trefwoorden
Versies (1)
- 20-06-17 20-06-17 -
Geüploaded op
20 juni 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Genetic Screening For HLA-B*5701 n Patients with HIV Week 1 NCT00340080
Genetic Screening For HLA-B*5701 Week 1 NCT00340080
- StudyEvent: ODM
Similar models
Genetic Screening For HLA-B*5701 Week 1 NCT00340080
- StudyEvent: ODM
C0449788 (UMLS CUI [1,2])
C0019993 (UMLS CUI [1,2])
C0019993 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,3])
C0019993 (UMLS CUI [1,2])
C0019993 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,3])
C0008952 (UMLS CUI [1,2])
C0008952 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,3])
C0449788 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,2])